In 2010, Salerno et al, investigated the action of PLX 4270 and PLX4032 in thyroid cancer cell lines (bearing either the BRAF mutation or the RET/PTC rearrangement) and in normal thyroid cells. The gene discussed is BRAF; the disease is thyroid cancer.